The management of peptic ulcer disease (PUD) has evolved significantly over the past few decades, driven by advancements in diagnostic techniques, treatment modalities, and our understanding of the pathogenesis of the disease. This article provides a comprehensive overview of these advancements and their implications for healthcare professionals.
Research has identified Helicobacter pylori infection and non-steroidal anti-inflammatory drugs (NSAIDs) as the two primary causes of PUD. Understanding these etiological factors has revolutionized PUD management, with eradication of H. pylori and minimization of NSAID use now forming the cornerstone of treatment.
Endoscopy remains the gold standard for diagnosing PUD. However, non-invasive tests such as urea breath test and stool antigen test for H. pylori have simplified the diagnostic process. Serology, although less accurate, can be useful in resource-limited settings.
Triple therapy, comprising a proton pump inhibitor (PPI) and two antibiotics, has been the standard treatment for H. pylori-associated PUD. However, due to increasing antibiotic resistance, quadruple therapy including a PPI, bismuth, and two antibiotics is now recommended. For NSAID-induced ulcers, discontinuation of NSAIDs, if possible, and PPI therapy are advised.
Prophylaxis with PPIs or H2 receptor antagonists is recommended for high-risk patients on NSAIDs. Additionally, the use of selective cyclooxygenase-2 inhibitors can reduce the risk of PUD in these patients. Vaccination against H. pylori is a promising preventive measure, but it is still in the research phase.
Advancements in the understanding, diagnosis, and treatment of PUD have significantly improved patient outcomes. However, the increasing prevalence of antibiotic resistance poses a challenge, necessitating further research in this field. Healthcare professionals must stay abreast of these developments to provide optimal care for patients with PUD.
1.
For the treatment of vestibular schwannomas in neurofibromatosis type 2, stereotactic radiosurgery has been found to be effective.
2.
FDA Advisors Recommend Galleri Multicancer Blood Test
3.
Women who miss their first mammogram face higher risk of breast cancer death, study finds
4.
Thriving while surviving: Understanding the social needs of cancer survivors
5.
Can Accelerated Salvage RT Improve Prostate Cancer Control?
1.
Fatigue and Work Participation in Blood Disease: A Comprehensive Review
2.
First-Line Immuno-Hematology Examinations: Essential Diagnostic Tools for Patient Care
3.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
4.
The Algorithmic Revolution: How AI is Reshaping Precision Oncology from Bench to Bedside
5.
Childhood Cancer Prevention Through Modifiable Exposure Reduction
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
3.
Understanding Common Causes of Abnormal Blood Counts
4.
Hematologic Fatigue and Work Function: Clinical Implications, Pathophysiology, and Management
5.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation